Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,894 | 374 | 1,503 |
| Samples | 1,577 | 312 | 1,251 |
| Peptides | 1,280 | 219 | 1,105 |
Function
STAB2 · Stabilin 2
This gene encodes a large, transmembrane receptor protein which may function in angiogenesis, lymphocyte homing, cell adhesion, or receptor scavenging. The protein contains 7 fasciclin, 15 epidermal growth factor (EGF)-like, and 2 laminin-type EGF-like domains as well as a C-type lectin-like hyaluronan-binding Link module. The protein is primarily expressed on sinusoidal endothelial cells of liver, spleen, and lymph node. The receptor has been shown to bind and endocytose ligands such as hyaluronan, low density lipoprotein, Gram-positive and Gram-negative bacteria, and advanced glycosylation end products. Supporting its possible role as a scavenger receptor, the protein has been shown to cycle between the plasma membrane and lysosomes. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000388887 | Q8WWQ8 | 1,894 | 1,280 |
Gene Properties
Recurrent Mutations
All 1280 amino-acid changes on canonical ENST00000388887 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in STAB2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in STAB2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Melanoma | 31/210 15% | 270/1899 14% |
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| Endometrial Carcinoma | 16/42 38% | 54/612 9% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 62/810 8% |
| Non-Small Cell Lung Carcinoma | 33/304 11% | 83/1390 6% |
| Hodgkins Lymphoma | 6/16 38% | 3/122 2% |
| Neuroendocrine Tumour | 23/154 15% | 18/577 3% |
| Acute Myeloid Leukemia | 5/90 6% | 0/0 0% |
| Other Solid Cancers | 5/94 5% | 81/1515 5% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 7/133 5% |
| Unknown | 0/10 0% | 2/29 7% |
| Small Cell Lung Carcinoma | 2/9 22% | 37/752 5% |
| Colorectal Carcinoma | 34/143 24% | 117/3239 4% |
| Gastric Carcinoma | 11/74 15% | 67/1809 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Chondrosarcoma | 3/14 21% | 0/75 0% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Bladder Carcinoma | 4/58 7% | 27/956 3% |
| Cervical Carcinoma | 1/35 3% | 12/422 3% |
| Ewings Sarcoma | 6/63 10% | 3/262 1% |
| Hepatocellular Carcinoma | 2/46 4% | 58/2210 3% |
| Thyroid Gland Carcinoma | 3/45 7% | 40/1592 3% |
| Germ Cell Tumour | 2/25 8% | 3/169 2% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Osteosarcoma | 5/45 11% | 0/166 0% |
| Esophageal Squamous Cell Carcinoma | 16/51 31% | 39/2550 2% |
| Biliary Tract Carcinoma | 3/54 6% | 18/950 2% |
| Plasma Cell Myeloma | 4/44 9% | 3/305 1% |
Mutation Distribution
Where STAB2 is mutated · all tissues, split by cell line vs tissue
How many mutations in STAB2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,894 mutations in STAB2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|